Mn Services Vermogensbeheer B.V. Cuts Stock Position in Catalent, Inc. (NYSE:CTLT)

Mn Services Vermogensbeheer B.V. cut its position in Catalent, Inc. (NYSE:CTLT) by 2.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 71,200 shares of the company’s stock after selling 1,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Catalent were worth $4,004,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also bought and sold shares of CTLT. Nisa Investment Advisors LLC lifted its stake in Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after buying an additional 185 shares during the last quarter. Lindbrook Capital LLC grew its position in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the last quarter. GAMMA Investing LLC increased its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares during the period. Czech National Bank grew its stake in shares of Catalent by 0.7% in the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares during the last quarter. Finally, BNP Paribas Asset Management Holding S.A. boosted its holdings in shares of Catalent by 1.9% during the fourth quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock worth $802,000 after purchasing an additional 328 shares during the period.

Catalent Stock Up 0.3 %

Shares of NYSE:CTLT traded up $0.18 during midday trading on Friday, hitting $59.44. 1,314,158 shares of the company’s stock were exchanged, compared to its average volume of 2,150,449. Catalent, Inc. has a 12 month low of $31.80 and a 12 month high of $60.20. The company has a market cap of $10.76 billion, a PE ratio of -9.74, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The stock has a 50 day moving average price of $57.98 and a 200-day moving average price of $56.85.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Barclays lifted their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. Finally, StockNews.com assumed coverage on Catalent in a report on Sunday. They issued a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $56.83.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders have sold a total of 14,810 shares of company stock valued at $858,941 over the last 90 days. Insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.